ropinirole has been researched along with Hallucinations in 5 studies
Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ropinirole XL/PR was titrated/continued, and adjusted as appropriate during the maintenance phase (maximum 24 mg/d)." | 2.82 | Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease. ( Asgharian, A; Ellis, J; Jimenez, T; Makumi, CW; Shaikh, S; VanMeter, S, 2016) |
| " In the group of patients with prior dopamine-agonist therapy, more patients reported adverse events in the ropinirole group (90% versus 79%, p < 0." | 2.70 | A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. ( Brooks, DJ; Brunt, ER; Korczyn, AD; Montastruc, JL; Stocchi, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Makumi, CW | 1 |
| Asgharian, A | 1 |
| Ellis, J | 1 |
| Shaikh, S | 1 |
| Jimenez, T | 1 |
| VanMeter, S | 1 |
| Nissen, T | 1 |
| Newman, EJ | 1 |
| Grosset, KA | 1 |
| Daghem, M | 1 |
| Pal, G | 1 |
| Stewart, M | 1 |
| Odin, P | 1 |
| Macphee, GJ | 1 |
| Grosset, DG | 1 |
| Pae, CU | 1 |
| Marks, DM | 1 |
| Han, C | 1 |
| Patkar, AA | 1 |
| Yamamoto, T | 1 |
| Brunt, ER | 1 |
| Brooks, DJ | 1 |
| Korczyn, AD | 1 |
| Montastruc, JL | 1 |
| Stocchi, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169[NCT00632736] | Phase 3 | 419 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AEs, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, were collected to obtain data on the safety, tolerability, and benefit of ropinirole XL. SAEs, defined as AEs that are fatal, life threatening, disabling/incapacitating, resulting in hospitalization or prolongation of a hospital stay, a congenital abnormality/birth defect, or any important medical occurrence that the investigator regards as serious based on medical judgment, were also collected. st. med., study medication. (NCT00632736)
Timeframe: 13 February 2004 through 31 March 2010
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Participants (Par.) reporting at least one AE | Par. reporting at least one SAE | Par. with drug-related AEs | Par. with AEs leading to withdrawal | |
| Ropinirole XL | 365 | 109 | 213 | 106 |
"The patient preference question assessed the participant's preference for either dosing regimen of study drug, once a day versus three times a day. Participants were asked to respond to the following question to assess preference: Please indicate whether you preferred taking your Parkinson's tablets 3 times a day or once a day. Wk, Week." (NCT00632736)
Timeframe: Week 4 and Week 26
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Very much preferred three times a day, Wk 4, n=74 | Much preferred three times a day, Week 4, n=74 | Preferred three times a day, Week 4, n=74 | Both regimens are about the same, Week 4, n=74 | Preferred once a day, Week 4, n=74 | Much preferred once a day, Week 4, n=74 | Very much preferred once a day, Week 4, n=74 | Very much preferred three times a day, Wk 26, n=87 | Much preferred three times a day, Week 26, n=87 | Preferred three times a day, Week 26, n=87 | Both regimens are about the same, Week 26, n=87 | Preferred once a day, Week 26, n=87 | Much preferred once a day, Week 26, n=87 | Very much preferred once a day, Week 26, n=87 | |
| Ropinirole XL | 2 | 0 | 4 | 5 | 17 | 18 | 28 | 4 | 1 | 2 | 4 | 14 | 20 | 42 |
2 trials available for ropinirole and Hallucinations
| Article | Year |
|---|---|
Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Back Pain; Delayed-Action Preparations; Dopami | 2016 |
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Drug Thera | 2002 |
3 other studies available for ropinirole and Hallucinations
| Article | Year |
|---|---|
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Confidence Intervals; Disorders of Excessive Somnolence; | 2012 |
A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?
Topics: Antidepressive Agents; Depressive Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Resi | 2008 |
Ropinirole as compared with levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Hallucinations; Humans; Indoles; Levodopa; Parkinson | 2000 |